Skip to content
Home > Investors & media > Announcements & presentations > 2012 > Strong Q3 - 2012 FY Targets Reiterated
 

Announcements

RB Press release - 24/10/2012
Strong Q3 - 2012 Full Year Targets Reiterated

Results at a Glance
Q3
£m
% change actual exchange
% change constant exchange
YTD £m
% change actual exchange
% change constant exchange
Net Revenue
2,422
-1
+4
  7,091 0  +4
 - Like-for-like growth*
   
+5
       
+4
Net Revenue by Segment
- ENA
- LAPAC


1,185
584


-4
+1


0
+9

3,442
1,736

-4
+6
  

-1
+11
- RUMEA 358 +1  +6 1,077  +3  +8
- Food
72
+1
0
  228  +5  +3
Total ex RBP
- RB Pharmaceuticals
  2,199
223
 -2
+7
 +4
+6
 6,483
608
 0
+7
 +4
+6
Total Net Revenue
2,422
 -1
+4
  7,091 0
+4
Net Revenue by Category
- Health
- Hygiene
- Home
- Portfolio brands
557
907
505
158
+2
-1
-3
-13

+6
+5
+3
-5

1,461
2,786
1,465
543
0
+2
-3
-7


+3
+6
+1
-1

* Like-for-like (“LFL”) growth excludes the impact of changes in exchange rates, major acquisitions  and disposals.

Highlights:

  • Year to date like-for-like (LFL) net revenue growth (ex RBP) of +4%, driven by strong Emerging Markets Areas (EM) growth.
  • Strong Q3 LFL growth +5% (+5% ex RBP).
  • Europe North America (ENA) Q3 LFL growth +2%. This improved performance was driven by higher brand equity investment (BEI), a good start for the new Mucinex Fast Max and a stabilising promotional environment in laundry care and Vanish.
  • YTD global growth driven by Dettol/Lysol, Harpic, Finish, Gaviscon, Durex and Vanish.
  • RBP – volume (mg) market share of Film grown to 60% up from 48% at the end of 2011.

Commenting on these results, Rakesh Kapoor, Chief Executive Officer, said:

“Reckitt Benckiser’s strong third quarter results were underpinned by an excellent performance in emerging markets and an improved performance in Europe North America. Growth came from all core Areas and categories. RBP continues to make very good progress with Suboxone sublingual film. I am very pleased that our new strategy and our renewed commitment to managing the business for the long term are showing encouraging results.

Our results give us the confidence to reiterate our FY 2012 target of like-for-like net revenue growth* of 200bps above our market growth rate. We now expect market growth to be at the top end of the 1-2% range. We continue to expect to maintain full year operating margins.*”

*ex RBP